Related references
Note: Only part of the references are listed.Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors
Yaxi Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor
Jonathan E. Wilson et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases
Michael R. Michaelides et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren M. Lasko et al.
NATURE (2017)
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz et al.
CELL (2013)
Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition
Feng Wang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation
Qihuang Jin et al.
EMBO JOURNAL (2011)
Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases
David C. Bedford et al.
EPIGENETICS (2010)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function
Ling Wang et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2008)
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator
Xin Liu et al.
NATURE (2008)
CBP and p300: HATs for different occasions
E Kalkhoven
BIOCHEMICAL PHARMACOLOGY (2004)
CREB-binding protein and p300 in transcriptional regulation
N Vo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)